Week 11: Crohn's Disease Flashcards
State what factors is associated with the Crohn’s Disease Activity Index score.(7)
No. of liquid stools.
Ab. pain
General wellbeing
No. of extraintestinal complications.
Use of anti-diarrhoeal medications.
Presence of ab. mass.
Haematocrit
Weight
What are the points range of CDAI? (3)
0-600 points
Remission = < 150
Moderate = > 220
Severe = > 300
Outline the treatment options for inducing remission in a patient with Crohn’s Disease. (3)
1st line: CS
2nd line: Thiopurine/MTX
3rd line: Biologics
What is the first line tx for inducing remission in a px with Crohn’s Disease? (3)
CS:
- Offer monotherapy with conventional glucocorticosteroid (prednisolone, methylprednisolone or IV hydrocortisone)
- This introduces remission in px with FIRST presentation or single inflammatory exacerbation of CD in a 12-month period.
What alt. tx option can be given to px with CD if they can’t tolerate the first line? (2)
Px with ≥1 distal ileal, ileocaecal or right-sided colonic disease who decline/can’t tolerate/CS is contranidicated, give Budesonide.
Budesonide = less effective than trad. glucocorticosteroid but has fewer s/e.
Give e.g. of CS used for inducing remission in CD. (10)
Severe cases: IV Hydrocortisone 100mg (can go up to 500mg QDS)
Oral:
- Prednisolone 30-40mg daily in the morning.
- Consider oral budesonide (Entocort/Budenofalk) if prednisolone is c/i or declined = effective in ileal disease due to site of release.
- Tapering - more severe the exacerbation, the slower the schedule should be. (Av. 5mg/week)
- Need of adjusting / slow down to cover intro. of aza/6mp (3 months to effect)
Topical:
- Suppositories = proctitis
- Enemas = effective up to splenic flexures.
What other treatment option is available for px’s who decline/can’t tolerate or trad. glucocorticosteroid is c/i in CD? (2)
Give 5-Aminosalicylate for a first presentation or single inflammatory exacerbation in 12-month period.
5-ASA = less effective than trad. glucocorticosteroid/budesonide but has fewer s/e than trad. glucocorticosteroid.
Explain the 2nd line therapy which would be considered as add-on therapy for CD. (3)
Add Azathioprine/6-Mercaptopurine to trad. glucocorticosteroid or budesonide if:
- there are ≥ 2 inflammatory exacerbations in a 12-month period
- glucocorticosteroid dose can’t be tapered.
When would MTX be considered as add-on treatment for CD? (2)
Azathioprine + 6-MP = not tolerated/c/i.
Explain the 3rd line tx option for inducing remission in CD. (3)
Biologics:
- Can be used as monotherapy if 1st and 2nd line options are c/i or not tolerated.
- Can be used in combination with immunomodulators.
Explain the prescribing safety of Thiopurines. (8)
Azathioprine:
- Pro drug, metabolised by xanthine oxidase to mercaptopurine.
6-Mercaptopurine:
- Azathioprine’s metabolite
- May be better tolerated and more effective for some px.
Assess TPMT before offering Azathioprine/Mercaptopurine:
- Don’t offer Azathioprine/Mercaptopurine if TPMT is very low or absent.
- Consider AZA/6-Mer at low dose if TPMT activity = < normal but not deficient.
What pre-treatment bloods/monitoring is considered for thiopurines? (5)
FBC
LFT
CRP
U+E
Renal Finction
What pre-tx screening is used for thiopurines? (4)
Hep. B + C
HIV
Varicella
EBV
What are the dosing regimens for AZA + 6-Mer? (2)
Azathioprine = 2-2.5mg/kg daily.
6-Mercaptopurine = 1-1.5mg/kg daily.
What counselling points should be given to patient who are taking thiopurines for CD? (5)
Blood tests - weekly for 1 month, then 3 months.
Avoid direct sunlight.
Avoid live vaccines
Increased risk of infection, cancer + bone marrow suppression:
- Px warned about bone marrow suppression development i.e. infection/unexplained bleeding/bruising,
- Report to GP ASAP!